Supplementation of Vitamin D in Patients With Type 2 Diabetes and Hypertension

NCT ID: NCT02204527

Last Updated: 2017-01-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-10-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In patients with type 2 diabetes, the effects on blood pressure of vitamin D has been shown to be variable. Thus, the goal of this proposal is to evaluate the effect of vitamin D supplementation in patients with type 2 diabetes and hypertension

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This study was a randomized, double-blind, placebo-controlled clinical trial on 40 outpatients with hypertension and type 2 diabetes were recruited.

Patients were allocated into two equal groups of 20 by computer-generated randomly permutated codes. the subjects were randomly assigned to 1 of 2 groups: Group 1 received a single dose (100.000 IU) of oral supplementation with cholecalciferol (vitamin D3). Group 2 received matching placebo capsules containing microcrystalline cellulose.
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

vitamin D3

supplementation of 100.000 IU of vitamin D3

Group Type EXPERIMENTAL

supplementation of 100.000 IU of vitamin D3

Intervention Type DIETARY_SUPPLEMENT

supplementation of vitamin D ( with 2 pills of Addera D3 (50.000IU each pill))

Placebo pill

Placebo

Group Type PLACEBO_COMPARATOR

placebo pill

Intervention Type DIETARY_SUPPLEMENT

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

supplementation of 100.000 IU of vitamin D3

supplementation of vitamin D ( with 2 pills of Addera D3 (50.000IU each pill))

Intervention Type DIETARY_SUPPLEMENT

placebo pill

Placebo

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

supplementation of 100.000 IU of vitamin D3: Addera D3 (50.000IU each pill) Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* type 2 diabetes
* hypovitaminosis D
* hypertension

Exclusion Criteria

* pregnant or lactating
* patients using vitamin D supplementation
* using drugs that interfere on vitamin D metabolism (corticosteroids, anticonvulsants)
* illicit drug use
* diseases such as chronic renal failure (serum creatinine greater than 2.0 mg/dl)
* liver cirrhosis
* alcoholism
* dementia
* malignant disease that compromises the 5-year survival,
* digestive tract (malabsorption) diseases
* BMI\> 40 kg / m2
Minimum Eligible Age

30 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Federal University of Rio Grande do Sul

OTHER

Sponsor Role collaborator

Hospital de Clinicas de Porto Alegre

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mirela Jobim de Azevedo

Mirela Jobim Azevedo

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

HCPA, Hospital de Clinicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil

References

Explore related publications, articles, or registry entries linked to this study.

de Paula TP, Moreira JSR, Sperb LF, Muller MEP, Steemburgo T, Viana LV. Efficacy of single-dose cholecalciferol in the blood pressure of patients with type 2 diabetes, hypertension and hypovitaminoses D. Sci Rep. 2020 Nov 12;10(1):19611. doi: 10.1038/s41598-020-76646-6.

Reference Type DERIVED
PMID: 33184328 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

140415

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Styrian Vitamin D Hypertension Trial
NCT02136771 COMPLETED PHASE4
Vitamin D for the Prevention of Diabetes Type 2
NCT00685594 COMPLETED PHASE2/PHASE3